Effective management of type 2 diabetes and metabolic syndrome: beyond glucose control

Abstract

Get full access to this article

View all access options for this article.

References

Alberti KG Tight glycaemic control:the key to improving the management of type 2 diabetes . Br J Diabetes Vasc Dis 2005;5:184-5.

Nice. Management of type 2 diabetes - management of blood pressure and blood lipids, October 2002.

Gale EA The myth of the metabolic syndrome. Diabetologia 2005;48: 1679-83.

Eckel RH , Grundy SM , Zimmet PZ The metabolic syndrome. Lancet 2005;365:1415-28.

Grundy SM , Cleeman JI , Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement . Circulation 2005;112:2735-52.

Alexander CM , Landsman PB , Teutsch SM , Haffner SM NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-14.

Malik S. , Wong ND , Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults . Circulation 2004;110:1245-50.

Wong ND Cardiovascular risk assessment in the metabolic syndrome, screening for subclinical disease, and implications for treatment. Br J Diabetes Vasc Dis 2005;5:305-14.

Wild SH , Byrne CD Treatment of lipids to reduce cardiovascular disease risk among people with the metabolic syndrome or type 2 diabetes. Br J Diabetes Vasc Dis 2005;5:315-19.

10.

Feher MD , Elkeles RS Fenofibrate in type 2 diabetes: The FIELD study. Br J Diabetes Vasc Dis 2005;5:330-3.

11.

Van Gaal LF , Peiffer F. , Ballaux D. Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid. Br J Diabetes Vasc Dis 2005;5:344-50.

12.

2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.

13.

Schachter M. Blood pressure reduction in the metabolic syndrome and type 2 diabetes: current concepts. Br J Diabetes Vasc Dis 2005;5:320-4.

14.

Williams B. , Poulter NR , Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-85.

15.

Beevers DG

The end 5. Beevers DG. The end of beta blockers for uncomplicated hypertension?

Lancet 2005;366:1510-12.

16.

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.

17.

Donnelly R. Managing cardiovascular risk in patients with diabetes. Br J Diabetes Vasc Dis 2005;5:325-9.

18.

Strippoli GF , Craig M. , Deeks JJ , Schena FP , Craig JC Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.

19.

Gaede P. , Vedel P. , Larsen N. , Jensen GV , Parving HH , Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93.

20.

Yki-Jarvinen H. The PROactive study: some answers, many questions . Lancet 2005;366:1241-2.